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ORIGINAL RESEARCH
Phenome- Wide Analysis of Short- and 
Long- Run Disease Incidence Following 
Recurrent Pregnancy Loss Using Data From 
a 39- Year Period
David Westergaard, PhD ; Anna Pors Nielsen, MD; Laust Hvas Mortensen, PhD;  
Henriette Svarre Nielsen, MD, DMSc; Søren Brunak , PhD
BACKGROUND: It is unclear how recurrent pregnancy loss (RPL) impacts disease risk and whether there is a difference in risk 
between women with or without a live birth before RPL (primary versus secondary RPL). We investigated the disease risk 
following RPL, and whether there was a difference between primary and secondary RPL.
METHODS AND RESULTS: Using population- wide healthcare registries from Denmark, we identified a cohort of 1 370 896 ever- 
pregnant women aged 12 to 40 years between 1977 and 2016. Of this cohort, 10 691 (0.77%) fulfilled the criteria for RPL 
(50.0% primary RPL). Average follow- up was 15.8 years. Incidence rate ratios were calculated in a phenome- wide manner. 
Diagnoses related to assessment and diagnosis of RPL and those appearing later in life were separated using a mixture 
model. Primary RPL increased the risk of subsequent cardiovascular disorders, including atherosclerosis, cerebral infarction, 
heart failure, and pulmonary embolism, as well as systemic lupus erythematosus, chronic obstructive pulmonary disease, 
anxiety, and obsessive- compulsive disorder. Women with secondary RPL had no increased risk of cardiovascular disorders. 
However, we observed an increased risk of gastrointestinal disorders such as irritable bowel syndrome and intestinal malab-
sorption, as well as mental disorders and obstetric complications.
CONCLUSIONS: RPL is a risk factor for a spectrum of disorders, which is different for primary and secondary RPL. Screening 
following RPL explains some associations, but the remaining findings suggest that RPL influences or shares cause with 
cardiovascular disorders, autoimmune disorders, and mental disorders. Research into the pathophysiology of RPL and later 
diseases merits further investigation.
Key Words: Bayesian statistics ■ epidemiology ■ pregnancy ■ recurrent pregnancy loss ■ women’s health
Recurrent pregnancy loss (RPL) is a condition that affects 1% to 3% of couples, depending on its precise definition.1,2 While the definition of RPL is 
not fully consistent across the world, it has historically 
been defined as 3 or more consecutive pregnancy 
losses (PL), and this is the definition used in Denmark 
and this study.3 With increasing number of losses, 
the frequency of euploid losses increases while the 
chance of a live birth decreases.4–6 RPL is divided into 
2 categories: primary (no live birth before losses) and 
secondary RPL (at least 1 live birth before losses). Prior 
Nordic studies report that 40% to 48% of cases are 
secondary RPL, but in some countries this may be as 
high as 61%.1,7,8
RPL is a multifactorial condition that, in addition to 
fetal causes, have multiple known female risk factors 
Correspondence to: Søren Brunak, PhD, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 
Blegdamsvej 3A, DK-2200 Copenhagen, Denmark. E-mail: soren.brunak@cpr.ku.dk or Henriette Svarre Nielsen, MD, DMSc, Recurrent Pregnancy Loss Unit, 
Department of Obstetrics and Gynecology, Hvidovre Hospital, DK-2650 Hvidovre, Denmark. E-mail: henriette.svarre.nielsen@regionh.dk 
Supplementary Materials for this article are available at https://www.ahajo urnals.org/doi/suppl/ 10.1161/JAHA.119.015069
For Sources of Funding and Disclosures, see page 8.
© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.  This is an open access article under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use 
is non- commercial and no modifications or adaptations are made. 




 http://ahajournals.org by on July 29, 2020
J Am Heart Assoc. 2020;9:e015069. DOI: 10.1161/JAHA.119.015069 2
Westergaard et al Disease Incidence After Recurrent Pregnancy Loss
such as autoimmune diseases, endocrine disorders, 
and uterine malformations.2,9 Risk factors differ be-
tween women with primary and secondary RPL. Male 
risk factors have been investigated less, but include 
chromosomal abnormalities, sperm DNA fragmenta-
tion, and age.10
In recent years, PLs and RPL have been suggested 
or identified as a risk factor for cardiovascular dis-
ease (CVD) and malignancies, although the evidence 
is ambiguous for the latter.11–16 The association with 
CVD has been further explored in a study that found 
first- degree relatives of women with RPL had an in-
creased risk of CVD.17,18 It has yet to be investigated 
if the risk is different between women with primary 
and secondary RPL. Some factors associated with a 
delayed time to pregnancy and infertility, such as en-
dometriosis, polycystic ovary syndrome, and diabetes 
mellitus, have a clear association to disease later in 
life, including malignancies, autoimmune diseases, 
and CVD.19–21 Moreover, obstetric complications have 
also been associated with an increased risk of CVD.22 
Despite RPL having a major impact on the affected 
couples, both mentally and physically, the cause and 
lifelong consequences are poorly understood.23,24 
Our hypothesis is that RPL and PLs not attributed 
to aneuploidy are associated with later disease, and 
that women with primary and secondary RPL have 
quite different risk profiles in terms of later disease. 
Identifying novel associations could lead to a patho-
physiological understanding that can improve the 
take- home baby rate, long- term maternal health, and 
reduce the health gap between men and women.
In this study, we compare primary and secondary 
RPL in a phenome- wide analysis using a nationwide 
cohort based on 1 370 896 women.
METHODS
The study was approved by the Danish Data Protection 
Agency (ref: 2015- 54- 0939 and SUND- 2017- 57) and 
Danish Health Authority (ref: FSEID- 00001627 and 
FSEID- 00003092). Informed consent and assess-
ment of the proposal in scientific ethical commit-
tees are not required for registry- based research in 
Denmark. Permission to access and analyze data can 
be obtained following approval from the Danish Data 
Protection Agency and the Danish Health Authority.
Study Design and Setting
This observational population was identified using the 
nationwide Danish Patient Registry and the Danish 
Medical Birth Registry. We included women aged 12 
to 40 years with at least 1 live birth or PL in the pe-
riod between January 1, 1977 and October 5, 2016. 
Women with multiple births (twins or higher order) were 
excluded. The population totaled 1 370 896 women.
Women with RPL were followed from the date of 
meeting the exposure until the end of follow- up (criteria 
until death or October 5, 2016).
Each woman with RPL was matched with 20 
women from the population without RPL. The women 
were matched based on year of birth and number of 
previous live births. The matched comparison group 
of women without RPL was followed for the outcomes 
from the same date of the woman with RPL they were 
matched to (ie, only the hospital admissions occurring 
on or after the date of RPL) and matching was used in 
the analysis. Women with RPL were divided into pri-
mary and secondary RPL based on the parity history 
before the date of RPL.
Outcomes were identified using several nationwide 
registries that cover all hospital admissions in Denmark 
(see Data S1 for a description).25
We identified 10 691 women who fulfilled the cri-
teria for RPL (50.0% primary) (defined in the next 
section). The number of years the women were 
CLINICAL PERSPECTIVE
What Is New?
• Recurrent pregnancy loss (RPL) is associated 
with disease later in life; understanding the link 
between RPL and subsequent disease patterns 
is crucial to identify prevention and treatment.
• Women experiencing primary and secondary 
RPL have different subsequent disease pat-
terns, notably within the cardiovascular, autoim-
mune, mental, and endocrine disease spectrum.
• Only primary RPL is associated with later car-
diovascular disease.
What Are the Clinical Implications?
• Primary and secondary RPL should be consid-
ered as 2 separate risk factors for later disease.
• Clinicians should include pregnancy history 
(including information about miscarriages) when 
assessing disease risk in a clinical setting and in 
study designs.
• Primary RPL is especially important for the 
assessment of cardiovascular disease risk.
Nonstandard Abbreviations and Acronyms
PL pregnancy loss
RPL recurrent pregnancy loss
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followed varied by outcome, but the average num-
ber of person- years was 1  782  238  years (range 
1 231 217–1 799 076 years) for women with primary 
RPL and the matched group, and 1 744 736  years 
(range 1 155 427–1 763 733 years) for women with 
secondary RPL and the matched group. Across all 
outcomes, the median follow- up time for women was 
15.8 years, ranging from 11.6 to 16.4 years for each 
specific outcome.
Pregnancy Loss and Recurrent Pregnancy 
Loss
PLs were identified from hospital admissions in the 
Danish National Patient Registry (Table). PLs occurring 
8 weeks before or after a molar pregnancy, induced 
abortion, or extrauterine pregnancy were disregarded 
(Table). In Denmark, every child showing signs of life 
at delivery is categorized as a live birth irrespective of 
gestational age. If there is no sign of life at delivery it 
is considered a PL before the 28th completed weeks 
of gestation and a stillbirth thereafter. This definition 
was changed starting from 2004 when stillbirth was 
counted from 22nd completed weeks of gestation. 
We filtered out diagnoses that were repeated within a 
medically unreasonable period of time: (1) <22 weeks 
between 2 live or still births, (2) <90  days between 
2 PLs, termination of pregnancy, molar or ectopic 
pregnancies, (3) <22  weeks between a PL, induced 
abortion, or an extrauterine or molar pregnancy and 
a stillbirth or livebirth, and (4) <30 days between a live 
or still birth and a PL, termination of pregnancy, or an 
extrauterine or molar pregnancy.
Cases of RPL were identified using hospital dis-
charge codes (Table) or by 3 consecutive PLs. The 
date of RPL diagnosis was defined as the date of the 
third PL or RPL diagnosis, whichever came first.
In the matching process, we used 1  370  339 
women from the total population. The median number 
of unique matched women per outcome was 186 752, 
ranging from 133 875 to 187 355.
Outcomes
In the phenome- wide analysis, we investigated 
International Classification of Diseases, Tenth Revision 
(ICD-10) codes at the third level that had a prevalence 
of ≥0.1% in women with RPL (626 diagnoses). ICD-10 
codes related to birth, PL, and termination of preg-
nancy were excluded (O00–O08 and O80–O84), as 
well as codes from ICD-10 chapters 19, 20, 21, and 
22. Only the first instance of a diagnosis code was 
included.
Differentiating Early From Late Disease 
Occurrences
Some of the diagnoses with an increased risk are be-
cause of investigations at an RPL clinic. To differenti-
ate the diagnoses found during investigations at RPL 
clinics and later in life, we fitted a log- normal mixture 
model. The optimal number of components was de-
termined using the Bayesian Information Criteria. For 
each diagnosis code with an increased risk, the time 
from RPL diagnosis until the outcome occurred was 
summarized as the median. Time distributions were 
visualized as histograms that binned multiple diagno-
ses into 1 bin.
Statistical Analysis
Incidence rate ratios (IRR) were estimated using a hi-
erarchical Bayesian Poisson log- linear model with 
time in 3- year bands. As covariates we included the 
age, binned into 11 groups (Table S1), and previous 
number of live births. A model was fit separately for 
women with primary and secondary RPL, respectively. 
Bayesian posterior distributions were summarized as 
95% uncertainty intervals (UI). To account for multiple 
Table. ICD-8 and ICD-10 Codes Used to Identify Recurrent Pregnancy Loss, Pregnancy Loss, and Molar and Extrauterine 
Pregnancies
Diagnosis ICD-8/ICD-10 Surgery Procedures
Recurrent pregnancy loss 6430x, Y6439, N96.x, O26.2 ··· ···
Missed abortion 6346x, 6451x, O02.1, O02.1A ··· ···
Miscarriage 6438x, 6439x, O03.x ··· ···
Extrauterine pregnancy 63109, 6311x, 63129, 63139, 63149, 
6315x, 63169, 63199, O00.x
66100, KLBCx, KMCBx, BKHE0, BKHE8x
Molar pregnancy 63190, 63429, 63460, 6450x, D39.2, 
O01.x, O02.0,
Abortion (induced) 6400x, 6401x, 6402x, 6409x, 6410x, 
6411x, 6412x, 6413x, 6414x, 6415x, 
6416x, 6417x, 6419x, 64209, 64219, 
64229, 64239, 64299, 6455x, 6456x, 
6458x, O04.x, O05.x, O06.x, O07.x
63680, 94520, KLCHx, 
KLWW00,
BKKG1, BKXG1
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testing, we calculated the false discovery rate using the 
Benjamini and Hochberg method. An association was 
deemed significant if the false discovery rate was <5%. 
We defined a prior structure that takes into account the 
chapter structure in the ICD-10 terminology (see Data 
S1 and Figure S1 for a thorough evaluation of the priors 
and the model). Distributions of time from RPL diagno-
ses until outcome were modeled using a log- normal 
mixture model, and the number of components was 
selected using the Bayesian Information Criteria (Table 
S2). Additional details on the statistical procedures are 
provided in Data S1. All data were analyzed using stan 
v2.18, python v2.7, and R v3.1.3.
RESULTS
Out of a pool of 1 310 unique ICD-10 codes assigned 
to women after RPL, we investigated 615 diagnoses 
with a cumulative incidence proportion of at least 0.1% 
in women with RPL. We found 151 and 127 diagnoses 
with an elevated IRR in primary and secondary RPL, 
respectively. These covered very heterogeneous types 
of disease (Figure  1, Data S1), and included CVDs, 
obstetric diagnoses, autoimmune diseases, mental 
disorders, gastrointestinal disorders, and respiratory 
diseases. We also observed 7 diagnoses with a RR 
lower than 1 (all in women with primary RPL), which 
were all related to complications of labor and delivery 
(Data S1).
We identified an “early” and “late” component for both 
primary and secondary RPL (Figure 2, Data S1). The 
median time to each diagnosis for women with RPL is 
available in Data S1. In women with secondary RPL, the 
“late” component had a mean value of 11.06 (SD=3.16) 
years after the diagnosis. Diagnoses that only had an 
increased risk in women with secondary RPL included 
irritable bowel syndrome (IRR=1.32, 1.10–1.60 95% UI) 
and intestinal malabsorption (IRR=1.67, 1.11–2.45 95% 
UI). Mental disorders included recurrent depressive 
disorders (IRR=1.35, 1.17–1.55 95% UI) and mixed per-
sonality disorders (IRR=1.58, 1.11–2.24 95% UI).
The late component was found to have a mean of 
12.6 (SD=4.53) after the primary PRL diagnosis and 
contained 141 diagnoses. Strikingly, for many CVDs 
we did not observe an increased risk in women with 
secondary RPL (Figure  3). This included atheroscle-
rosis (IRR=1.90, 1.30–2.75 95% UI), cerebral infarction 
(IRR=1.83, 1.36–2.38 95% UI), heart failure (IRR=1.93, 
1.40–2.63 95% UI), and pulmonary embolism 
(IRR=1.64, 1.16–2.29 95% UI). Other diseases included 
lupus erythematosus (IRR=3.79, 2.45–5.78 95% UI), 
systemic lupus erythematosus (IRR=2.52, 1.34–4.31 
95% UI), chronic obstructive pulmonary disease 
(IRR=1.56, 1.24–1.96 95% UI), and type 2 diabetes 
mellitus (IRR=1.92, 1.62–2.27 95% UI). Several mental 
disorders were also found, including anxiety (IRR=1.29, 
1.08–1.53 95% UI) and substance abuse because of 
smoking (IRR=2.0, 1.65–2.42 95% UI).
Several disorders were found to have an increased 
risk in both subtypes, such as thyroid disorders (hypo-
thyroidism and thyroiditis), asthma, reaction to severe 
stress, depressive episodes, risk of mental disorders 
because of substance abuse of alcohol, and gastro-
intestinal disorders (gastroesophageal reflux disease, 
and gastritis and duodenitis). The disorders all be-
longed to the late component.
The early component was found to have a mean 
of 2.26 (SD=0.78) years for primary RPL and 1.68 
(SD=0.56) years for secondary RPL. The compo-
nent contained diagnoses routinely investigated as 
part of the RPL evaluation (eg, uterine malforma-
tions, balanced chromosomal rearrangements, and 
abnormal immunological findings in serum). Cervical 
malformations, which is not a part of the standard 
evaluation, was also found to have an increased risk. 
Additionally, there were many diagnoses related to 
obstetric complications and pregnancy for both pri-
mary and secondary RPL. Certain obstetric compli-
cations were only found to have an increased risk in 
secondary RPL, such as placenta previa (IRR=3.67, 
95% UI 2.80–4.77), premature rupture of membrane 
(IRR=2.67, 95% UI 2.30–3.06), intrapartum hemor-
rhage (IRR=2.53, 95% UI 1.55–3.98), gestational 
hypertension (IRR=1.96, 95% UI 1.45–2.63), pre- 
eclampsia (IRR=2.29, 95% UI 1.81–2.87), puerperal 
sepsis (IRR=2.55, 95% UI 1.80–3.54), and placen-
tal abruption (IRR=2.91, 95% UI 2.15–3.86).The lat-
ter also had an increased risk in primary RPL, albeit 
lower (IRR=1.32, 95% UI 1.05–1.67).
DISCUSSION
In this study, we performed the largest registry- 
based phenome- wide study to date of longitudinal 
disease incidence in RPL. The population comprised 
1 370 896 women, of which 10 691 had 3 or more 
consecutive PLs. By investigating diagnoses occur-
ring after RPL, we identified distinct spectrums of 
complications for primary and secondary RPL. The 
diagnoses were divided into “early” and “late” com-
plications: The “late” component included multiple 
complications in heterogeneous disease domains, 
such as CVDs, autoimmune diseases, mental dis-
orders, digestive system disorders, and respira-
tory diseases. The disorders occurred, on average, 
>10 years after the RPL diagnosis, and there was a 
distinct set of diseases associated with primary and 
secondary RPL. The “early” complications contained 
many previously established risk factors for RPL 
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These included coagulation disorders, congenital 
malformations of the female genital organs, and au-
toimmune diseases. The early component also con-
tained obstetric complications, with the majority seen 
only after secondary RPL. We found no evidence that 
women with RPL had an increased risk of malignan-
cies, irrespective of the subtype. The large population 
of women, both with and without RPL, allowed us to 
Figure 1. Diagnoses occurring more frequently following recurrent pregnancy loss (RPL) across 
18 ICD-10 chapters.
The points have been scattered in the vertical direction to improve readability. Each point represents the 
median value from the posterior distribution. A, Diagnoses with an elevated risk for women with primary 
RPL (180 diagnoses). B, Diagnoses with an elevated risk for women with secondary RPL (172 diagnoses). 
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investigate late- state complications in a phenome- 
wide manner. This has historically not been possible, 
because of the small cohort sizes often used. The 
findings we present here are of wide interest as we 
identify primary and secondary RPL as a risk factor 
and an early indicator of later disease.
The basis for this study was nationwide data 
collected over a 39- year period. Reporting to the 
Danish registries used in this study is mandatory. 
An important source of bias is unregistered PLs. 
This includes PLs handled at home, in general or 
gynecological practice. This leads to some women 
being erroneously classified as not having RPL, lead-
ing to an underestimation of the IRR. Furthermore, 
the RPL definition depends on the reliability of the 
identification of PLs in the Danish National Patient 
Registry. However, this condition has previously 
been estimated to have a positive predictive value of 
97%.26 Lack of information from the Danish Medical 
Birth Register could result in women being classified 
wrongly as primary and secondary RPL; nonethe-
less, the Danish Medical Birth Register is considered 
Figure 2. Distribution of the median time between a recurrent pregnancy loss (RPL) diagnosis 
and 1 of the 180 and 172 diagnoses that are more frequent following primary RPL and secondary 
RPL, respectively.
The histogram indicates the observed data points, whereas the 2 density plots indicate the 2 components 
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to be complete.27 The registries do not contain com-
plete information on smoking status or body mass 
index. Additionally, we did not have any information 
on socioeconomic status or whether the partner was 
the same for all pregnancies, which could confound 
our findings. Furthermore, we did not include the dis-
ease history before RPL, which could also confound 
the results. Still, many women experiencing RPL are 
not properly investigated before referral to a spe-
cialist clinic, and it is therefore not possible to take 
this into account. We also note that the infant and 
maternal mortality in Denmark is extremely low.28,29 
This is partially because of universal health care and 
referral to specialist clinics involved in the monitor-
ing and treatment of, for example pregnant women 
with diabetes mellitus and heart disease. Therefore, 
we would not expect to see many PLs in the cohort 
because of, for example, uncontrolled diabetes mel-
litus. Additionally, there are no known causal factors 
for RPL with the exception of embryonal malforma-
tions, and it is thus difficult to control for pre- existing 
conditions related to RPL. The probability of an early 
PL is highly correlated with age. Since we did not 
have information on the karyotype of the product 
Figure 3. Diagnoses unique to either primary or secondary recurrent pregnancy loss, divided 
into the 2 “early” and “late” groups determined from the mixture model analysis.
Each point represents the median value from the posterior distribution. The coloring scheme is as in 
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of conception, we have tried to minimize the con-
founding effect from aneuploidy by only including 
women younger than 40 years of age. Moreover, be-
cause of the lack of paternal information, we could 
not account for those cases where there is a pater-
nal chromosomal translocation. A mixture of cases 
because of aneuploidy or paternal translocations 
would weaken the signal, and we could thereby have 
missed some associations, or underestimated the 
relative risks. This study was based on population 
data from a 39- year period. While this is helpful for a 
long follow- up period, changes and developments in 
medical practice may influence the results. However, 
we did attempt to mitigate this effect by matching 
women born in the same year. Lastly, because of the 
large number of outcomes studied in this phenome- 
wide analysis, we cannot rule out chance findings. 
Nevertheless, we have attempted to mitigate this by 
advanced statistical modeling and we also note that 
the large number of diagnoses associated with RPL 
remains striking and is consistent within certain do-
mains of disease, which merits further investigation.
We found that primary and secondary RPL, when 
considered separate phenotypes, are followed by a 
unique spectrum of complications later in life. Our ob-
servations in the domain of CVDs and obstetric compli-
cations are in accordance with prior studies.12,13,30,31 Yet, 
previous studies of CVD and PL have not been stratified 
by subtype, and here we demonstrate that primary RPL 
drives the observed associations. This is an important 
distinction, because this could point towards shared 
pathophysiology only present in women with primary 
RPL and could serve as the basis for future screening 
and risk- assessment profiles. Furthermore, we found 
that systemic lupus erythematosus (SLE), a recognized 
risk factor for RPL, also was significantly more frequent 
in women after an RPL diagnosis and belonged to the 
“late” component. This can be explained in at least 2 
different ways. First, if SLE and RPL share a common 
pathophysiological cause, our findings indicate that this 
cause has not always manifested fully at the time of RPL 
diagnosis and evaluation or it could be that RPL itself 
increases the risk of SLE, possibly through increased 
microchimerism.32,33 Lastly, the increased risk of men-
tal disorders and substance abuse could possibly be 
mitigated by a closer follow- up and referral to therapy.
There are large discrepancies across health in men 
and women.34 Here, we have tried to elucidate how the 
pregnancy history contributes to disease. The identi-
fication of complications across the full spectrum of 
disease present a new set of challenges that must be 
examined in- depth clinically to uncover the cause and 
close the gap in health care between men and women. 
Identification of clinically relevant subtypes is an im-
portant aspect of precision medicine, both to tailor 
screening and therapy to reduce the disease burden, 
but also to prevent overdiagnosis and unnecessary 
invasive procedures in an already vulnerable patient 
group. We have demonstrated this aspect in our dis-
tinction between primary and secondary RPL, in which 
CVD only had an increased risk in 1 subtype. Indeed, 
RPL may very well be an early initiator of disease, dis-
ease maintenance, and disease progression. However, 
the exact relationship between RPL and chronic dis-
eases remains to be elucidated. Most importantly, our 
results indicate that RPL is an early marker of a wide 
range of diseases. We therefore speculate that, in the 
future, fertility history will be a core part of most risk 
prediction models across diverse clinics in health care. 
Considering the full pregnancy history including prior 
PLs is thus relevant when evaluating and predicting the 
future risk of disease in women.
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The basis for the study was the Danish National Patient Registry (NPR), the Danish Psychiatric Registry (PSYK), the 
Danish Cancer Registry (TUMOR), and the Danish Medical Birth Registry (DMBR).35–37 Hospital admissions from NPR 
and PSYK included all inpatient, outpatient, and emergency contacts. Discharge diagnoses were coded according to ICD 
version 8 (ICD-8) in the period 1977-1993, and ICD-10 starting from 1994. ICD-8 codes were mapped to ICD-10 using 
the translation provided by Pedersen et al.38 ICD-10 has a hierarchical structure and consists of four levels (chapters, 
blocks, level 3 codes, and level 4 codes). Level 4 codes are the most specific codes. Here, we used the level 3 codes. Not 
using the most specific code is a trade-off between power and specificity, as the most specific codes will be assigned to 
a lower number of people. The NPR and PSYK also contains operations and procedures, coding according to a Danish 
classification until 1995 (available at https://sundhedsdatastyrelsen.dk/da/rammer-og-retningslinjer/om-
klassifikationer/sks-klassifikationer/download-sks, last visited 16th September 2018). Since 1995, operations have been 
coded according to the Nordic NOMESCO Classification of Surgical Procedures. Procedures are coded according to a 
Danish classification, (available at http://www.medinfo.dk/sks/brows.php?s_nod=1616, last visited 16th September 2018) 
starting from 1995. The Danish Cancer Registry is a population-wide registry that was established in 1943. Reporting to 
the registry has been mandatory since 1987. The diagnoses from the Danish Cancer Registry has been coded using ICD-
10 since 1978 (in 2003 codes from 1978-2003 was translated into ICD-10). The MFR has collected information on all 
births in Denmark since 1973. This includes date of birth, gestational age, outcome of birth (liveborn / stillborn), and 
parental information. Women living in Greenland or the Faroe Islands were excluded from the analysis since the Danish 
National Patient Registry (DNPR) does not cover these countries. 
 
 
Bayesian Estimation and Inference 
All models were fitted using Stan v. 2.18.0 (http://mc-stan.org/).39 Stan is an open-source implementation of the 
Hamiltonian Monte Carlo No-U-Turn-Sampler (HMC-NUTS).40,41 HMC-NUTS is a Markov Chain Monte Carlo 
(MCMC) algorithm. For each model, four chains were run in parallel with different starting seeds. Each chain was run 
for 20,000 steps, of which 10,000 was used for warm-up and discarded prior to inference, with default parameters. HMC-
NUTS uses the warm-up steps to tune the hyper-parameters of the algorithm. The number of steps is much lower, 
compared to e.g. Gibbs sampling. This is due to the HMC-NUTS being much more efficient at exploring the posterior 
distribution and thus reaching the stationary distribution faster.40 We assessed converge of each model by computing the 
R-hat statistics, inspecting the tree-depth, and counting the number of divergences. The R-hat number is a quantitative 
description of the within and between chain variation for the different MCMC chains for each parameter, and is sometimes 
also referred to as the potential scale reduction factor.42 A large R-hat value indicates non-convergence. If the chains have 
converged, the R-hat value will be close to one. The tree-depth is a HMC-NUTS specific characteristic that puts an upper 
limit on the number of computations in each iteration. If the max tree-depth is reached post-warmup the HMC-NUTS 
will be similar to a random-walk MCMC, and can bias estimates.43 Lastly, divergences are a count of how many times 
HMC-NUTS had numerical problems (e.g. underflowing / overflowing, division by zero). This can be due to a bad model, 
problems in data, or ill-suited priors. Divergences are serious, as HMC-NUTS cannot explore the region of the posterior 
where they happen.44  
Here we define convergence if all R-hat values < 1.1, the tree-depth is not maxed at any point post warm-up, and there 
are no divergences. Inference was made by summarizing the posterior distribution into the Bayesian Uncertainty Interval 
(UI) and the probability that the interval is different from zero.45 We define the UI to be the 95% Highest Density Interval 
(HDI), which indicates the narrowest interval that spans 95% of the posterior distribution.46 We calculated the P-value as 
the probability that the effect was equal to or less than zero when the estimated mean value was greater than zero, and 
vice versa when the estimated mean value was less than zero, 
𝑃 = {
Pr⁡(𝑥 ≤ 0), ?̅? > 0
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The false discovery rate (FDR) was controlled using the Benjamini-Hochberg approach. We concluded that RPL was 
associated with an increased or decreased risk of later diagnosis if the FDR did not exceed 5%.  
 
 
Incidence Rate Ratio Estimation 
Estimation of the incidence rate ratio (IRR), was done using a Poisson log-linear model. We estimated the IRR by 
selecting a matched comparison group. Age was controlled by grouping the year of birth into twelve five-year intervals 
(Table S1). For every woman with RPL, twenty women without RPL were selected matched by the year of birth and 
number of live births priors to the matched time. If the outcome had occurred prior to the RPL diagnosis date, the woman 
was excluded from the analysis. Likewise, if the outcome had occurred prior to the exposure date in a matched woman, 
the woman was not eligible for the matched comparison group.  
The IRR was estimated using a Poisson log-linear model specified as shown in Equation 1 and Equation 2. The Poisson 
model is a piece-wise exponential survival model that approximates a Cox model under certain assumptions, one of them 
being a constant hazard over time. To relax this assumption, we divided the total time into three year intervals and included 
a covariate for each segment.  
𝒚𝒊⁡~𝑷𝒐𝒊𝒔𝒔𝒐𝒏(𝐞𝐱𝐩(𝜼𝒊)) 
Equation 1 
𝜼𝒊 = 𝜷𝟎 + 𝜷𝑹𝑷𝑳 ∗ 𝒙𝑹𝑷𝑳 +∑ 𝜷𝒊 ∗ 𝒙𝒊𝒊 + ∑ 𝜷𝒋 ∗ 𝒙𝒋𝒋 + ∑ 𝜷𝒑 ∗ 𝒙𝒑𝒑 + 𝐥𝐨𝐠(𝒄)  
Equation 2 
In the equation, yi is the number of women with the outcome, 𝑥𝑅𝑃𝐿  is an indicator variable for the RPL status, i is one of 
the fourteen hazard intervals (setting the first interval as reference),  j is one of the eleven age bins defined in Table S1 
(using the seventh bin as the reference level), and 𝑥𝑗 is an indicator variable for the age group, p is the parity group (1, 2, 
>=3, 1 being the reference level) and 𝑥𝑝 is an indicator for the parity group, c is the total number of person-years within 
that stratum. The parity coefficient was only included in the model for secondary RPL. The first age bin comprised years 
prior to 1945, as there were only very few women in the cohort born prior to 1945. The last age bin comprised everyone 
born in 1991 and onwards, as very few women with RPL was born after 1991. 
From the Poisson model, the parity and age-adjusted IRR is equal to the exponentiated value of the coefficient, i.e. 
exp⁡(𝛽𝑅𝑃𝐿).  
Table S1. Age bins used for adjusting the RR for age. 


















All outcomes, subscripted A, are jointly modelled in a Bayesian hierarchical model, in which each outcome has its own 
set of coefficients for the model. To complete the Bayesian model specification, we assign a prior to each coefficient in 















The priors for the intercept (𝛽0), time segment (𝛽𝑖), age-bin (𝛽𝑗), and parity (𝛽𝑝𝑎𝑟𝑖𝑡𝑦) were assigned weakly informative 
normal distributions centered around zero. The prior for the coefficient of interest for each outcome, 𝛽𝑅𝑃𝐿 , is assigned a 
student-t distribution with seven degrees of freedom, centered around zero, with a standard deviation determined from 
the data.  The centering around zero a priori expects that the IRR is equal to one, given that exp(0) = 1. The student-t 
distribution also has a large body of its probability mass close to zero, further augmenting the choice. The long tails may 
accommodate values that may fall outside a normal distribution.  
Rather than using an unpooled prior, that is, an independent prior on each outcome, we instead encoded the ICD-10 
hierarchy into the prior. E.g., diagnoses regarding the circulatory system all have the same prior. In total, we included 
eighteen ICD-10 chapters in the present study, each indexed by 𝜏 in Equation 8. This is a natural grouping of diagnosis 
based on anatomical or functional group, and may improve how well the model fits the data, thereby leading to better 
inference. The hierarchical prior induces regularization of estimates, a process known as Bayesian shrinkage.47. The 
shrinkage process can safeguard against spurious findings, which can sometimes be driven by small sample sizes where 
it is difficult to get a sufficiently certain estimate of the coefficients. To ascertain the effect of the shrinkage procedure, 
we compared the beta values for the RPL coefficient estimated from our Bayesian procedure, with the ones estimated 
from a Maximum Likehood Estimate (Figure S1). We observed that in the vast majority of cases, the values estimated 
using the full Bayes procedure are below the diagonal, indicating that they are being shrunk towards the null value. We 
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Lastly, we randomly shuffled the exposure status (RPL) to ascertain that there were no errors in data. In the randomly 







A log-normal mixture model was employed to model the multimodal distributions observed in the time between an RPL 
diagnosis and complications. A mixture model is a probabilistic model that assumes that the observed data has been 
generated by a discrete number of distributions, k, Equation 10.  




A log-normal distribution was chosen since only the time after an RPL diagnosis was investigated, and hence the 
distribution was bounded to positive numbers. Each diagnosis with an elevated RR was considered a data point, and the 
time between the RPL and diagnosis was summarized as the median across all patients due to the heavy tail arising from 
the long follow-up period. The model assigns a probability to each diagnosis of belonging to a specific component in the 
model. A diagnosis was assigned to the component that had the highest probability. The model was fit using the R library 
mixR v2.3.14. The number of components was selected using the Bayesian Information Criteria (BIC, Table S2). 
Inspection of the model post-fit was performed to visually determine if the fit looked reasonable.  
 
Table S2. Bayesian Information Criteria for mixture model. 
 K=1 K=2 K=3 
Primary 991.75 910.76 918.19 
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Figure S1. Shrinkage plot comparing the Bayesian median estimate of the beta value versus the 
maximum likelihood estimate.  
 
The values for the beta coefficient are typically below the diagonal, indicating that the values are being shrunk towards 
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